Thyroid Eye Disease: Multidisciplinary Management of Treatment-Associated Hyperglycemia (CE Monograph)

Activity Description and Purpose

This educational activity is intended to help clinicians identify patients with thyroid eye disease (TED) who require intervention for elevated blood glucose levels prior to treatment for TED with the insulin-like growth factor 1 receptor antagonist teprotumumab. Clinicians will also learn to apply evidence to manage patients who require intervention for glycemic control during treatment for TED with teprotumumab. The desired results of this activity are for eye care professionals to use a multidisciplinary approach to increase their ability to identify and manage hyperglycemia in patients who require treatment of TED.

Target Audience

This educational activity is intended for optometrists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Identify patients with thyroid eye disease who require intervention for elevated blood glucose prior to treatment
  • Apply evidence to manage patients who require intervention for glycemic control during treatment of thyroid eye disease
Course summary
Available credit: 
  • 1.50 COPE
Course opens: 
Course expires: 


Andrea Kossler, MD, FACS (Chair)
Associate Professor of Ophthalmology
Stanford University School of Medicine
Stanford, California
Director of Ophthalmic Plastic and Reconstructive Surgery
Director, Multidisciplinary Thyroid Eye Disease Clinic
Co-Director of the Orbital and Ocular Oncology Service
Byers Eye Institute
Palo Alto, California

Sonalika Khachikian, MD
Monument Health Rapid City Clinic
Rapid City, South Dakota

Lilly Wagner, MD
Ophthalmic Plastic and Reconstructive Surgeon
Mayo Clinic
Rochester, Minnesota

Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.


Sonalika Khachikian, MD, is a consultant for Amgen Inc; is on the speakers bureau for Amgen Inc; and is on the advisory board of Novo Nordisk A/S*.

Andrea Kossler, MD, is a consultant for Acelyrin, Inc, Amgen Inc, Argenx, Genentech, Inc, and Immunovant, Inc; is an advisory board member of Arrowhead Pharmaceuticals; and is a contracted researcher for Amgen Inc, Kriya Therapeutics, Lassen Therapeutics, Sling Therapeutics, and Viridian Therapeutics, Inc.

Lilly Wagner, MD, has no relevant commercial relationships to disclose.

Peer Reviewer

Hadi Kaakour, MD, was formerly an advisory board member of Alimera Sciences*.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

* The financial relationship existed during the past 24 months but has now ended

Accreditation Statement

 COPE approved for 1.5 CE credits for optometrists.
COPE Course ID: 89852-SD (Asynchronous)
COPE Course Category: Treatment & Management of Ocular Disease


This activity, COPE Activity Number 127888, is accredited by COPE for continuing education for optometrists.

Disclosure of Commercial Support

MedEdicus has received commercial support from Amgen Inc for this activity in the form of an unrestricted educational grant.

The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs or devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Sponsored by

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the State University of New York College of Optometry, MedEdicus LLC, or Amgen Inc.

This CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 309

Available Credit

  • 1.50 COPE
Please login or register to take this course.

Clicking Register/Take course indicates that you have reviewed the CE information for this activity.